EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer
Study Details
Study Description
Brief Summary
Head & neck (H&N) cancer is the eighth most common cancer in the UK. Advanced H&N cancer which has come back after treatment or has spread to other parts of the body is incurable and the average life expectancy of these patients is less than a year. New drugs called immune checkpoint inhibitors work with the patient's own immune system to fight cancer. They are used in the clinic to treat a number of cancers, including H&N cancer. It may be possible to make immune checkpoint inhibitors more effective by combining drugs that work in different ways. In effect, attacking the cancer from different angles. Cetuximab is a well-established drug that works by blocking signals that tell cancer cells to grow and divide into more cells. It also engages with the immune system within the tumour. The trial aims to see if giving cetuximab along with an immune checkpoint inhibitor drug called avelumab is better at treating advanced H&N cancer than giving avelumab on its own.
These two drugs have not been given together before, so to start with, the investigator plans to enrol a small number of patients and give the patients avelumab + cetuximab to make sure the combination is safe at the doses chosen. After this, the investigator plans to enrol 114 patients with advanced H&N cancer. Half the patients will be treated with avelumab alone and the other half with avelumab + cetuximab. Both drugs are given intravenously in the hospital once every 2 weeks.
Treatment lasts for up to a year and patients will be followed up for up to 2 years from the time they enter the study. Patients will be recruited from around 15 hospitals in the UK. Recruitment would be expected to start in the second quarter of 2018 and it will take about 29 months (Safety run-in: 5 months; Phase II: 24 months) to recruit all the patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This is a randomised phase II study comparing the efficacy of avelumab alone with avelumab + cetuximab combination in patients with platinum-resistant advanced or metastatic head & neck cancer. The randomised phase II part of the trial will be preceded by a safety run-in.The objective of the safety run in is to make sure the combination of cetuximab and avelumab at the doses selected for the study are safe and tolerable.
In phase II, the main question the investigator wants to answer is whether or not giving avelumab and cetuximab together is better than giving avelumab alone to treat patients with head and neck cancer that have had previous treatment with cisplatin and whose cancer has come back or spread to other parts of the body. The investigator will compare the number of patients in each group whose cancer has not gotten any worse 6 months after joining the study.
The phase II part of the trial will recruit patients with head & neck squamous cell carcinoma only. However, during the safety run-in, patients with other types of squamous cell carcinomas will also be eligible.
Target accrual:
Safety run-in: up to 16 patients with squamous cell carcinomas; Phase II: 114 patients with head & neck squamous cell cancer
The safety run-in will recruit patients in cohorts of 3 at a time and all patients will be treated with the combination. The safety run in is a dose de-escalation design. That is, patients will be given the dose that is planed for use in phase II and if this proves not tolerable, the dose of cetuximab will be de-escalated and another cohort of patients will be recruited. The investigator will conclude the combination is safe and tolerable if less than 33% of patients who are treated experience side effects that lead to a dose reduction. The purpose is to ensure the safety of the combination prior to starting phase II, as these drugs have not been given together before. However, there is evidence from previous studies that these types of drugs can be combined safely. The trial aims to complete the safety run-in within 5 months and the phase II study within 24 months. The entire duration of recruitment is expected to be 29 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Avelumab + cetuximab Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year. Avelumab + cetuximab combination therapy: Cycle 1 Day 1: Cetuximab 500* mg/m2 given IV over approx 3 hrs Day 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr All other cycles: - Days 1 and 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr *Cetuximab dose will be dependent on outcome of safety run-in. There must be a 60 minute break between the administration of cetuximab and avelumab. |
Drug: Avelumab
Avelumab 10 mg/kg given IV
Drug: Cetuximab
Cetuximab 500* mg/m2 given IV
*Cetuximab dose will be dependent on outcome of safety run-in.
|
| Other: Avelumab monotherapy Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year. Avelumab monotherapy will be given as follows: All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour |
Drug: Avelumab
Avelumab 10 mg/kg given IV
|
Outcome Measures
Primary Outcome Measures
- Safety run-in: Occurrence of dose limiting toxicity [From start of cycle 1 (each cycle is 28 days) upto six weeks.]
Detailed adverse event monitoring will be conducted according to CTCAE v4.03. Patients experiencing any of the following adverse events related to either cetuximab or avelumab during the DLT period will be considered to have experienced a DLT: Any grade 3 or 4 adverse reaction requiring a dose reduction of cetuximab Any adverse reaction resulting in a more than a 14 day treatment delay for any agent.
- Phase II: Disease control rate at 24 weeks after randomisation [From randomisation upto 24 weeks]
Assessed using iRECIST
Secondary Outcome Measures
- Objective response (iCR or iPR) at 6 and 12 months [6 months and 12 months after registration/randomisation]
Using iRECIST
- Disease control at 6 and 12 months [6 and 12 months after registration/randomisation]
Using iRECIST
- Best overall response [From start of treatment to 24 months after registration, or upto start date of a new treatment for their disease, whichever came first, assessed up to 24 months.]
Using iRECIST
- Duration of response [From the date of the first response assessment showing iCR or iPR to the date of the response assessment documenting iPD according to iRECIST, assessed up to 24 months.]
Using iRECIST
- Overall survival [Time from registration/randomisation to death from any cause, assessed up to 24 months.]
- Time to Progression [From date of registration/randomisation to date of first documented progression, assessed up to 24 months.]
- Progression free survival [From date of registration/ randomisation to date of first documented progression, assessed up to 24 months.]
- Frequency and severity of adverse events [From informed consent to 90 days post last IMP treatment]
- Treatment related dose delays or treatment discontinuation [From start of treatment to end of treatment, assessed up to 12 months.]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Safety run in: Histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma that is considered incurable by local therapies
Phase II: Histologically/cytologically confirmed recurrent/metastatic squamous cell carcinoma of the head and neck that is considered incurable by local therapies.
-
Prior treatment with a platinum agent (either for recurrent/metastatic disease; or as part of radical intent multimodality treatment if disease has recurred within 6 months). (NB: This criterion is not applicable for the safety run-in).
-
No previous treatment with cetuximab for metastatic/recurrent disease
-
Age ≥18 years
-
WHO Performance Status 0 or 1
-
Measurable disease according to RECIST v1.1
-
Adequate bone marrow function
-
Adequate liver function
-
Adequate renal function
-
Adequate venous access for administration of treatment and collection blood samples for exploratory biological samples
-
Willing to have a new biopsy (NB: This criterion is not applicable for the safety run-in).
-
Life expectancy of >3 months
-
Women of child-bearing potential and male patients with partners of child-bearing potential must agree to use adequate contraception methods from date of informed consent, which must be continued for 120 days after completion of trial treatment.
-
Able to give informed consent, indicating that the patient has been informed of and understands the experimental nature of the study, possible risks and benefits, trial procedures, and alternative options
-
Willing and able to comply with the protocol for the duration of the study, including the treatment plan, investigations required and follow up visits.
Exclusion Criteria:
-
Patients with undifferentiated nasopharyngeal or sino-nasal cancers.
-
Disease suitable for treatment with curative intent.
-
Prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent.
-
Treatment with any investigational agent within 4 weeks prior to the first dose of trial treatment.
-
Anti-cancer monoclonal antibody therapy within 4 weeks prior to randomisation
-
Chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to randomisation.
-
Persisting grade ≥2 toxicity related to prior therapy
-
Patients with concurrent or previous malignancy that could compromise assessment of the primary or secondary endpoints of the trial.
-
Women who are pregnant or breast feeding.
-
Grade 3 or 4 peripheral neuropathy.
-
Any serious and/or unstable pre-existing medical, psychiatric or other condition, or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
-
Patients who are not able to give informed consent for any reason.
-
Active central nervous system (CNS) metastases and/or carcinomatous meningitis
-
Hepatitis infection at screening
-
Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
-
Prior organ transplantation including allogenic stem-cell transplantation
-
Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
-
Active infection requiring systemic therapy
-
Has received a live vaccine within 28 days prior to first dose of trial treatment
-
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (n.b. the use of physiologic doses of corticosteroids may be approved after consultation with UCL CTC)
-
Active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent.
-
Current use of immunosuppressive medication
-
History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e. bronchiolitis obliterans, cryptogenic organising pneumonia), or evidence of active pneumonitis on screening chest CT scan. (History of radiation pneumonitis in the radiation field is permitted).
-
Significant cardiovascular disease
-
Known prior severe hypersensitivity to either investigational product or any component in their formulations, including known severe hypersensitivity reactions to monoclonal antibodies
-
Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis.
-
Patients with a history of keratitis, ulcerative keratitis or severe dry eye.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University College Hospital | London | United Kingdom | NW1 2PG |
Sponsors and Collaborators
- University College, London
- Merck KGaA, Darmstadt, Germany
Investigators
- Principal Investigator: Martin Forster, FRCP PhD, University College London Hospitals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UCL/17/0560